David Williamson has no position in any stocks mentioned. Max Macaluso, Ph.D. owns shares of Gilead Sciences. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Feb 7, 2014 at 6:30PM
In this final segment of Market Checkup, the Motley Fool's health-care focused investing show, analyst David Williamson explains why small-cap Cambrex Corporation is on his watchlist.
Headquartered right next to Super Bowl site MetLife Stadium, Cambrex is a life sciences company focused on making active pharmaceutical ingredients. Essentially, it makes the drugs the drug companies sell. In many ways Cambrex is almost more of an industrial stock than a health-care stock.
In this video, David highlights Cambrex's financial performance, why a mystery client has the rumor mill buzzing, and why investors should watch Cambrex's quaterly results.
- Feb 7, 2014 at 6:30PM
- Health Care